Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H21NO3 |
Molecular Weight | 239.3107 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
InChI
InChIKey=NDAUXUAQIAJITI-UHFFFAOYSA-N
InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3
Molecular Formula | C13H21NO3 |
Molecular Weight | 239.3107 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:37:47 UTC 2023
by
admin
on
Fri Dec 15 16:37:47 UTC 2023
|
Record UNII |
QF8SVZ843E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
NBK548685
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
WHO-ATC |
R03AK13
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
WHO-VATC |
QR03CC02
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
WHO-ATC |
R03AC02
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
WHO-VATC |
QR03AC02
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
NDF-RT |
N0000175779
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
WHO-ATC |
R03AL02
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
25.1
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
WHO-VATC |
QR03AK04
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
WHO-VATC |
QR03AL02
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
WHO-ATC |
R03AK04
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
FDA ORPHAN DRUG |
152501
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
WHO-ATC |
R03CC02
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
||
|
NDF-RT |
N0000009922
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ALBUTEROL
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless. Solubility: Soluble in 70 parts of water; soluble in ethanol (~750 g/l) TS; slightly soluble in ether R. Category: Antiasthmatic drug. Storage: Salbutamol should be kept in a well-closed container, protected from light. Definition: Salbutamol contains not less than 98.0% and not more than 101.0% of C13H21NO3, calculated with reference to the dried substance. | ||
|
SUB10422MIG
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
2083
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
100000091629
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
105
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
35763-26-9
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
SUPERSEDED | |||
|
435
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | RxNorm | ||
|
757417
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
DB01001
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
CHEMBL714
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
QF8SVZ843E
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
Albuterol
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
7206
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
2585
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
1012600
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
18559-94-9
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
SALBUTAMOL
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
DTXSID5021255
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
242-424-0
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
558
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
2549
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
D000420
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
m1480
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | Merck Index | ||
|
C215
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY | |||
|
QF8SVZ843E
Created by
admin on Fri Dec 15 16:37:47 UTC 2023 , Edited by admin on Fri Dec 15 16:37:47 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
ACTIVE ENANTIOMER->RACEMATE |
|
||
|
TARGET -> AGONIST |
SHORT-ACTING
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
BINDER->LIGAND |
|
||
|
INACTIVE ENANTIOMER->RACEMATE |
|
||
|
PARENT->INNOVATOR |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
IN-VIVO
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
catalysed almost exclusively by sulphotransferase (SULT) 1A3
|
||
|
METABOLITE -> PARENT |
catalysed almost exclusively by sulphotransferase (SULT) 1A3
MAJOR
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
ORAL, EXTENDED-RELEASE TABLET PHARMACOKINETIC |
|
||
Tmax | PHARMACOKINETIC |
|
HYDROFLUOROALKANE (HFA) INHALER PHARMACOKINETIC PHARMACOKINETIC PHARMACOKINETIC PHARMACOKINETIC |
|
||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
EXTENDED-RELEASE TABLET PHARMACOKINETIC |
|
||
Biological Half-life | PHARMACOKINETIC |
|
ORAL, INHALATION PHARMACOKINETIC PHARMACOKINETIC |
|
||